HNB
NGNE icon

Huntington National Bank’s Neurogene NGNE Stock Holding History

Huntington National Bank’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10
Closed -$364 – 4190
2024
Q2 		$364 Hold
10
– – ﹤0.01% 2480
2024
Q1 		$509 Buy
+10
New +$334 ﹤0.01% 2350

Other funds holding NGNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Huntington National Bank's NGNE Position: Q3 2024 in Review

Huntington National Bank sold out of Neurogene (NGNE) in Q3 2024, closing a stake of 10 shares — an estimated $364 sold.

Huntington National Bank first reported a position in NGNE in Q1 2024 and held it in 2 quarters. The position peaked at $509 in Q1 2024. 86 funds tracked by Wall St. Rank hold NGNE as of Q3 2024.

  • Huntington National Bank reported no remaining Neurogene position as of Q3 2024 after selling out during the quarter.
  • Huntington National Bank sold 10 Neurogene shares in Q3 2024, an estimated $364.
  • Huntington National Bank first reported a position in Neurogene in Q1 2024 and held it in 2 quarters.
  • Huntington National Bank's Neurogene position peaked at $509 in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Neurogene as of Q3 2024.

Based on Huntington National Bank's 13F filing for Q3 2024, filed 6 Nov 2024.